Peroxisome proliferator-activated receptor alpha (PPARα)

Overview

Peroxisome proliferator-activated receptor alpha (PPARα), encoded by the PPARA gene (Wikidata: Q18030677), is a ligand-activated transcription factor belonging to the nuclear receptor superfamily. It is expressed predominantly in tissues with high rates of fatty acid catabolism, including the liver, heart, skeletal muscle, and kidney. Upon activation by endogenous lipid ligands or synthetic agonists such as fibrate-class drugs, PPARα forms a heterodimer with the retinoid X receptor (RXR) and binds to peroxisome proliferator response elements (PPREs) in the promoter regions of target genes, thereby orchestrating the transcriptional programs governing fatty acid uptake, mitochondrial and peroxisomal β-oxidation, ketogenesis, and lipoprotein metabolism. Its central role in maintaining hepatic and systemic lipid homeostasis makes it a high-priority pharmacological target in metabolic liver diseases, dyslipidemia, and related cardiometabolic conditions.

Beyond its canonical lipid-regulatory functions, PPARα intersects with inflammatory signaling, mitochondrial quality control, and oxidative stress response pathways. It operates within a broader metabolic regulatory network alongside complementary nuclear receptors such as Peroxisome proliferator-activated receptor gamma (PPARγ), deacetylases such as Sirtuin 1 (SIRT1) (SIRT1), and antioxidant transcription factors such as nuclear factor erythroid 2-related factor 2 (NRF2). Dysregulation of PPARα activity has been linked to non-alcoholic and metabolic dysfunction–associated steatotic liver disease (MASLD), diabetic nephropathy, aging-related renal fibrosis, and dyslipidemia, underscoring its broad translational relevance.

Recent Publications Summary

Recent publications have continued to position Peroxisome proliferator-activated receptor alpha (PPARα) as a central regulator of hepatic lipid handling and fatty acid oxidation in metabolic liver disease. In high-fat diet models, peony seed oil improved serum lipid profiles, reduced hepatic cholesterol and triglyceride levels, and alleviated steatosis, with multi-omics analyses showing coordinated changes in fatty acid metabolism-related transcripts including Ppara and validation confirming increased hepatic Ppara expression 42411358Jul. Similarly, Miao medicine Jinshanxiaoke granules were reported to ameliorate metabolic dysfunction-associated steatotic liver disease through Ampk/Ppar-α and Pi3k/Akt-mediated restoration of hepatic lipid homeostasis 41990925Apr, while pedunculoside was described as targeting HNRNPA1 and modulating PPARα signaling to enhance mitochondrial fatty acid β-oxidation in MASLD 41671881Feb. In another hepatoprotective formulation study, self-assembling Gardenia pectin gel improved cholestatic liver injury and restored hepatic glycolipid metabolic homeostasis via geniposide-mediated PPARα activation 42097772May.

PPARα was also implicated in several studies of natural products and fermentation-derived interventions that improved lipid accumulation and liver injury. Aspergillus niger-fermented pine pollen reduced hepatic triglycerides and serum ALT in alcoholic fatty liver disease models, with mechanistic data showing suppression of lipogenesis through downregulation of PPARγ and SREBP-1c and promotion of fatty acid oxidation through upregulation of PPARα and CPT1 41762882Feb. A fibrate-derivative optimization study identified compound T2 as a hypolipidemic and hepatoprotective agent that significantly upregulated hepatic PPARα protein expression in hyperlipidemic mice 41679202Feb. In hyperuricemia research, biotransformation-derived metabolites from Astragalus membranaceus and Cordyceps militaris lowered serum uric acid and improved lipid parameters while activating the hepatic PPARα signaling pathway 41905012Mar. Gynura procumbens extract was also reported to modulate the PPARα pathway in diabetic kidney disease, alongside inhibition of NF-κB and increased antioxidant gene expression 41968655Apr.

Beyond liver and kidney disease, PPARα was linked to gut-derived lipid mediators and host-microbiota interactions. In diarrhea-predominant irritable bowel syndrome with insulin resistance, the fatty acid ethanolamide oleoylethanolamide acted as a PPARα agonist to upregulate the serotonin transporter and limit peripheral serotonin availability, while fecal microbiota transplantation from high-FAE donors or treatment with FAE-producing bacteria increased fecal FAE and alleviated symptoms via the PPARα-SERT axis 42320473Jun. In cholestatic liver disease, Wendan decoction was investigated for its effects on the gut-liver axis and fatty acid metabolism through the FXR/PPARα/CYP4A12A axis. Collectively, these studies reinforce PPARα as a recurring mechanistic node in interventions aimed at improving fatty acid oxidation, reducing hepatic lipid deposition, and modulating metabolic inflammation across diverse disease models.

What Changes, What Holds

1. PPARα remains a central hepatic lipid-oxidation node, but these studies mainly reinforce rather than revise that role
REINFORCES The new work stays within the Overview’s core account of PPARα as a regulator of fatty acid handling and metabolic liver disease. It adds more examples of upstream activators and disease models, but does not displace the established mechanism or broaden PPARα into a different kind of target. The practical takeaway is confirmation that hepatic PPARα signaling remains a recurring readout and intervention point in MASLD and cholestatic injury 42411358Jul41990925Apr.

2. These interventions strengthen the case for PPARα as a shared effector of lipid-lowering and hepatoprotective responses
REINFORCES The paragraph extends the existing view that PPARα promotes fatty acid oxidation and restrains lipid accumulation, now across fermented products, optimized fibrate-like chemistry, hyperuricemia models, and diabetic kidney disease. Nothing here contradicts the Overview; instead, it sharpens the idea that PPARα is a common downstream node in diverse metabolic interventions. The kidney signal is additive, not a new role that overturns prior understanding 41762882Feb41679202Feb.

3. PPARα is emerging as a gut-microbiota and serotonin-linked mediator, not just a hepatic lipid regulator
NEW DIRECTION The new work extends PPARα into gut-derived lipid mediators, microbiota transfer, and serotonin transport, areas the Overview does not cover. That does not conflict with its established metabolic role, but it does change how broadly the receptor is being used mechanistically: it is now being invoked in symptom control and host-microbe signaling, not only in fatty acid oxidation. The evidence is still early and model-based, so human validation is needed 42320473Jun.

Overview update candidates: PPARα as a gut-microbiota/serotonin-linked mediator; PPARα involvement in the FXR/PPARα/CYP4A12A gut-liver axis.